Reaction
Hypereosinophilic Syndrome reporting signals
As of the last recalculation, Hypereosinophilic Syndrome appears in 525 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is MEPOLIZUMAB (PRR 52.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Mepolizumab | 59 | 52.9 | 53.0 |
| Benralizumab | 17 | 34.8 | 34.8 |
| Imatinib Mesylate | 12 | 17.4 | 17.4 |
| Dupilumab | 57 | 5.1 | 5.1 |